Medical AI

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

Amidst AI hype, one company is betting on human expertise. Conscientia Health's clinician-led AI platform is making bold promises for mental healthcare.

A new AI platform, HeartFocus Link, connects to existing hospital ultrasound carts, offering guided training to help close a critical skill gap in cardiac imaging.

Gene Solutions' SPOT-MAS 10 test gains FDA Breakthrough Designation, accelerating its path to the U.S. market and heralding a new era in early cancer detection.

A new AI platform using smartwatches just got FDA's Breakthrough nod, promising to predict heart failure crises before they happen from home.

With a new CTO and a co-founder as CDO, Stellar Health is restructuring its tech leadership to accelerate its AI-driven value-based care platform.

The oncology AI firm's new funding will expand its platform, which helps top cancer centers make sense of complex patient data and improve trial matching.

A new partnership aims to deploy AI-powered imaging and advanced training across Asia Pacific, tackling the region's leading cause of death head-on.

A fivefold increase in one year, THINK Surgical’s miniature robot is reshaping orthopedics with its unique open platform and powerful industry partnerships.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.

This year's Shaw Prize honors scientists who turned a deadly leukemia into a curable disease and unraveled the secrets of stellar explosions.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

With new funding from Bregal Sagemount, LSPedia is set to advance its AI tools, moving beyond compliance to build a smarter, safer pharma supply chain.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.

ValGenesis's upcoming event explores AI's pivotal role in pharma validation, charting a course from digital systems to intelligent, compliant operations.

DePuy Synthes acquires novel radiofrequency tracking to move beyond the line-of-sight limits and invasive pins of current robotic joint surgery systems.